INVITATION Astellas kindly invites you to the Belgian Xtandi Launch Meetings: New treatment options in mCRPC: Where does Xtandi® fit in? Register now via www.xtandilaunch.be This meeting is supported by Only a few years ago, the therapeutic options for men with advanced prostate cancer were quite limited. Patients with distant recurrences were mostly treated with androgen-deprivation therapy; those with metastatic castration-resistant prostate cancer (mCRPC) received chemotherapy. Improved imaging techniques however, have created the new disease entity ‘oligometastatic disease‘ in which only a limited number of regions are involved. Is local treatment of these metastatic spots a valuable option for these patients? Another important development of the last few years is the increasing therapeutic arsenal to manage patients with mCRPC, including the androgen receptor targeting agent enzalutamide. From December onwards, enzalutamide will be reimbursed in Belgium. With the new treatment options, new questions arise. How can we reach the goal of administering the right treatment to the right patient at the right time? This meeting will provide insight in local therapy for recurrent prostate cancer and oligometastatic disease. The focus will be on best practice for treating men with mCRPC, with an emphasis on enzalutamide as second-line option after docetaxel. Interested to participate in one of these meetings? Please register via: www.xtandilaunch.be PROGRAMME New treatment options in mCRPC: Where does Xtandi® fit in? 19.00-19.30 Welcome drink & appetisers 19.30-19.45 Introduction by Astellas 19.45-20.15 Radiotherapy for recurrent prostate cancer 20.15-20.45 Enzalutamide in clinical trials: Efficacy, tolerability and quality of life 20.45-21.15 Enzalutamide in clinical practice: Discussion of clinical cases 21.15 Walking dinner This meeting is supported by BE/XTD/14/0021 DATA, LOCATIONS AND FACULTIES Tuesday 2 December (meeting in Dutch) Lamot • Mechelen Van Beethovenstraat 8-10 2800 Mechelen www.lamot-mechelen.be Dr. Piet Dirix (radiation oncologist) Prof. dr. Steven Joniau (urologist) Dr. Daisy Luyten (medical oncologist) Monday 15 December (meeting in French) Château de Colonster • Liège Université de Liège, Allée des Érables 4000 Liège www.colonster.ulg.ac.be Dr. Olivier De Hertogh (radiation oncologist) Prof. dr. Brieuc Sautois (medical oncologist) Prof. dr. David Waltregny (urologist) Tuesday 20 January (meeting in French) Le Palais De Plume • Ittre Rue Haute 8 1460 Ittre www.lepalaisdeplume.com Dr. Richard Burette (radiation oncologist) Prof. dr. Thierry Roumeguère (urologist) Dr. Thierry Gil (medical oncologist) Wednesday 21 January (meeting in Dutch) Auberge du Pêcheur • Sint-Martens-Latem Pontstraat 41 9831 Deurle - Sint-Martens-Latem www.auberge-du-pecheur.be Prof. dr. Gert De Meerleer (radiation oncologist) Dr. Peter Schatteman (urologist) Dr. Filip Van Aelst (medical oncologist) Organisation: Ismar Healthcare Leopoldplein 39 bus 1, 2500 Lier, Belgium Iris Schrooten: +32 473 33 47 62, Kristof Willems: +32 486 31 89 79 www.ismar.com Wednesday 14 January (meeting in French) Loungeatude • Ottignies-Louvain-la-Neuve Place Polyvalente (derrière La Ferme du Biéreau), 1348 Ottignies Louvain-la-Neuve www.loungeatude.be Dr. Marco Gizzi (medical oncologist) Dr. Sam Palumbo (radiation oncologist) Prof. dr. Bertrand Tombal (urologist) This meeting is supported by